Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
lilly.com

See what CB Insights has to offer

Investments

68

Portfolio Exits

23

Funds

1

Partners & Customers

10

Service Providers

3

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global healthcare company that unites caring with discovery to make life better for people around the world. Lilly works to discover and bring medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Eli Lilly and Company Headquarter Location

Lilly Corporate Center

Indianapolis, Indiana, 46285,

United States

800-545-5979

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Eli Lilly and Company

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Eli Lilly and Company in 3 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

D

Diabetes

1,750 items

M

Medical Devices

3,500 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

Eli Lilly and Company Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Eli Lilly and Company Rank

Research containing Eli Lilly and Company

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Eli Lilly and Company in 3 CB Insights research briefs, most recently on Sep 13, 2021.

Latest Eli Lilly and Company News

Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications

Dec 3, 2021

11/21 12/02/2021 | 11:31pm EST Message : *Required fields SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company ("Lilly") (NYSE: LLY), announce that the innovative PD-1 inhibitor sintilimab has been successfully included in the updated National Reimbursement Drug List ("NRDL") for all approved indications, according to the latest announcement from the China National Healthcare Security Administration ("NHSA"). The updated NRDL will officially take effect on January 1, 2022. A total of four approved indications for sintilimab are now included in the updated NRDL: Three indications for sintilimab have been included in the NRDL for the first time, as follows: in combination with pemetrexed and platinum chemotherapy for the first-line treatment of advanced or recurrent nonsquamous non-small cell lung cancer (nsq NSCLC) without sensitizing EGFR mutations or ALK rearrangements; in combination with gemcitabine and platinum chemotherapy for the first-line treatment of advanced or recurrent squamous non-small cell lung cancer (sq NSCLC); and in combination with BYVASDA® (bevacizumab biosimilar injection) for the first-line treatment of unresectable or advanced hepatocellular carcinoma (HCC). An indication for relapsed or refractory classic Hodgkin's lymphoma (cHL) after two lines or later of systemic chemotherapy, which was first included in the NRDL in 2019, has been successfully renewed this year. Dr. Michael Yu, Founder, Chairman and CEO of Innovent, stated, "Two years ago, sintilimab was the first and only PD-1 inhibitor included in the NRDL. This year, three additional first-line indications for sintilimab have been successfully included in the NRDL, further enhancing the accessibility of this anti-cancer drug and alleviating financial burden for Chinese patients and their families. We have witnessed the profound reform and rapid development of pharmaceutical industry in China, driven by the government's commitment to continuously support innovation and emphasize a healthier and better life for the people of China. Innovent is honored to be a part of the Chinese government's initiative to improve health, and are devoted to the deepening of the national health care reform. With our company's mission 'to develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people,' we hope to continue to work together with all relevant parties to improve drug affordability and accessibility, and contribute to the 'Healthy China 2030' initiative." Julio Gay-Ger, President and General Manager, Lilly China, stated, "In recent years, China has continued to intensify medical insurance reform, giving strategic priority to safeguarding people's health. As a multinational pharmaceutical company tied with China for over 100 years, Lilly always adheres to the philosophy of 'In China, For China', and actively participates in China's health reform, especially in the drug supply system. The indication expansion of sintilimab in the National Reimbursement Drugs List (NRDL) can further reduce the burden of healthcare, enabling the patients to afford innovative drugs and have a higher quality of life through persistent treatment. Lilly will continue to keep a close eye on the major healthcare challenges in China in the future, and play an important role in the country's 'all-round and full-cycle health' ecosystem, to support the accelerated implementation of the 'Healthy China 2030' initiatives." Mr. Min Liu, Chief Commercial Officer of Innovent, stated, "Sintilimab is the only PD-1 inhibitor in China with four major indications (1L nsq NSCLC, 1L sq NSCLC, 1L HCC and cHL) approved and included in China's NRDL. Particularly, lung cancer and liver cancer are two of the most prevalent tumor types in China, accounting for the first and third largest numbers of new cases each year – representing a large unmet medical need. We will proactively support the work of the government departments at all levels, cooperate with the implementation of medical insurance policies in all regions, and help relieve patients' economic burden to a further extent, to allow this high-quality immunotherapy product to benefit more lives of Chinese patients and their families." About Sintilimab Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is an innovative PD-1 inhibitor with global quality standards jointly developed by Innovent and Eli Lilly and Company. Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. In China, sintilimab has been approved and included in the National Reimbursement Drug List (NRDL) for four indications, including: The treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of nonsquamous non-small cell lung cancer In combination with gemcitabine and platinum chemotherapy, for the first-line treatment of squamous non-small cell lung cancer In combination with BYVASDA® (bevacizumab biosimilar injection) for the first-line treatment of unresectable or advanced hepatocellular carcinoma Additionally, Innovent currently has two regulatory submissions under review in China for sintilimab, for the first-line treatment of esophageal squamous cell carcinoma, and the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma. Additionally, three clinical studies of sintilimab have met their primary endpoints: Phase 2 study as second-line treatment of esophageal squamous cell carcinoma Phase 3 study as second-line treatment for squamous NSCLC with disease progression following platinum-based chemotherapy Phase 3 study in combination with BYVASDA® (bevacizumab biosimilar injection) and chemotherapy (pemetrexed and cisplatin) for EGFR-mutated nonsquamous NSCLC following EGFR-TKI treatment In May 2021, the U.S. FDA accepted for review the Biologics License Application (BLA) for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of nonsquamous non-small cell lung cancer. About Innovent Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 26 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 6 products officially approved for marketing in China – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection), Pemazyre® (pemigatinib oral inhibitor) and olverembatinib (BCR ABL TKI), a Biologics License Application (BLA) for sinitilimab accepted for review in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 15 molecules in clinical studies. Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. For more information, please visit: www.innoventbio.com . and www.linkedin.com/company/innovent-biologics/ . About Eli Lilly and Company Lilly is a global healthcare leader that unites caring with discovery to create medicines to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit  lilly.com and  lilly.com/newsroom . P-LLY About Innovent Biologics' strategic collaboration with Eli Lilly and Company Innovent entered into a strategic collaboration with Lilly focused on biological medicine in March 2015 – a groundbreaking partnership between a Chinese pharmaceutical company and a multinational pharmaceutical company. Under the agreement, Innovent and Lilly are co-developing and commercializing oncology medicines, including sintilimab, in China. In October 2015, the two companies announced the extension of their existing collaboration to include co-development of three additional antibodies targeting oncology indications. In August 2019, Innovent further entered into a licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China. The collaboration with Lilly is an example of how Innovent has established a comprehensive level of cooperation between China's innovative pharmaceuticals sector and the international pharmaceuticals sector in fields such as R&D, CMC, clinical development and commercialization. In August 2020,Lilly and Innovent announced a global expansion of their strategic alliance for sintilimab, whereby Lilly obtained an exclusive license for sintilimab for geographies outside of China and plans to pursue registration of sintilimab in the U.S. and other geographies outside of China. Note: TYVYT® (sintilimab injection) is not an approved product in the United States. BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States. TYVYT® (sintilimab injection, Innovent)

Eli Lilly and Company Investments

68 Investments

Eli Lilly and Company has made 68 investments. Their latest investment was in Fountain Therapeutics as part of their Series A - III on November 11, 2021.

CBI Logo

Eli Lilly and Company Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/18/2021

Series A - III

Fountain Therapeutics

$15M

Yes

5

10/26/2021

Series A

Mozart

$55M

Yes

5

10/5/2021

Seed VC

IpiNovyx Bio

$10M

Yes

7

9/20/2021

Series E

Subscribe to see more

$99M

Subscribe to see more

10

9/14/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/18/2021

10/26/2021

10/5/2021

9/20/2021

9/14/2021

Round

Series A - III

Series A

Seed VC

Series E

Series B

Company

Fountain Therapeutics

Mozart

IpiNovyx Bio

Subscribe to see more

Subscribe to see more

Amount

$15M

$55M

$10M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

5

7

10

10

Eli Lilly and Company Portfolio Exits

23 Portfolio Exits

Eli Lilly and Company has 23 portfolio exits. Their latest portfolio exit was Dicerna Pharmaceuticals on November 18, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/18/2021

Acq - Pending

$991

5

5/28/2021

Acquired

2

3/30/2021

Acquired

$991

11

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

11/18/2021

5/28/2021

3/30/2021

00/00/0000

00/00/0000

Exit

Acq - Pending

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

5

2

11

10

10

Eli Lilly and Company Acquisitions

25 Acquisitions

Eli Lilly and Company acquired 25 companies. Their latest acquisition was Protomer Technologies on July 14, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/14/2021

Seed VC

Acquired

4

1/22/2021

IPO

$991

$135M

Acq - P2P

10

10/15/2020

Grant

$991

$30M

Acquired

2

2/20/2020

PIPE

Subscribe to see more

$991

$99M

Subscribe to see more

10

2/15/2019

IPO

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

7/14/2021

1/22/2021

10/15/2020

2/20/2020

2/15/2019

Investment Stage

Seed VC

IPO

Grant

PIPE

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Total Funding

$135M

$30M

$99M

$99M

Note

Acquired

Acq - P2P

Acquired

Subscribe to see more

Subscribe to see more

Sources

4

10

2

10

10

Eli Lilly and Company Fund History

1 Fund History

Eli Lilly and Company has 1 fund, including Australia Biotech Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Australia Biotech Fund

Early-Stage Venture Capital

1

Closing Date

Fund

Australia Biotech Fund

Fund Type

Early-Stage Venture Capital

Status

Amount

Sources

1

Eli Lilly and Company Partners & Customers

10 Partners and customers

Eli Lilly and Company has 10 strategic partners and customers. Eli Lilly and Company recently partnered with Incyte on November 11, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

11/9/2021

Licensor

Incyte

United States

08:30 ET OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with ...

In December 2009 , Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases .

1

10/19/2021

Licensor

Innovent Biologics

China

Good news for Lilly as sintilimab hits the spot in lung cancer again

Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent 's sintilimab last year , and a new trial in lung cancer will raise its hopes of getting a good return on its investment .

1

10/4/2021

Partner

Boehringer Ingelheim

Germany

09:00 ET Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-M...

In January 2011 , Boehringer Ingelheim Corporation and Eli Lilly and Company announced an alliance that centers on compounds representing several of the largest diabetes treatment classes .

1

9/29/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

9/28/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

11/9/2021

10/19/2021

10/4/2021

9/29/2021

9/28/2021

Type

Licensor

Licensor

Partner

Partner

Partner

Business Partner

Incyte

Innovent Biologics

Boehringer Ingelheim

Country

United States

China

Germany

Subscribe to see more

Subscribe to see more

News Snippet

08:30 ET OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with ...

In December 2009 , Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases .

Good news for Lilly as sintilimab hits the spot in lung cancer again

Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent 's sintilimab last year , and a new trial in lung cancer will raise its hopes of getting a good return on its investment .

09:00 ET Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-M...

In January 2011 , Boehringer Ingelheim Corporation and Eli Lilly and Company announced an alliance that centers on compounds representing several of the largest diabetes treatment classes .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Eli Lilly and Company Service Providers

4 Service Providers

Eli Lilly and Company has 4 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Other

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Subscribe to see more

Provider Type

Other

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Eli Lilly and Company Team

52 Team Members

Eli Lilly and Company has 52 team members, including current Chief Executive Officer, David Ricks.

Name

Work History

Title

Status

David Ricks

Chief Executive Officer

Current

Anne E White

President

Current

Anat Ashkenazi

Chief Financial Officer

Current

Julie Gilmore

Chief Operating Officer

Current

Aarti Shah

Chief Information Officer

Current

Name

David Ricks

Anne E White

Anat Ashkenazi

Julie Gilmore

Aarti Shah

Work History

Title

Chief Executive Officer

President

Chief Financial Officer

Chief Operating Officer

Chief Information Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.